Previous 10 | Next 10 |
home / stock / bmra / bmra articles
- Expansion into new offices within current major groups, including Northeast and Ohio; Expansion into new major group in Texas. - Average quarter...
Collaborators at the University of Michigan will present new Data on InFoods® IBS in the DDW Irritable Bowel Syndrome (IBS) Clinical Session...
IRVINE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company leading the way in innovative gastr...
Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to ...
Shares of Motus GI Holdings, Inc. (NASDAQ: MOTS) shares fell sharply in pre-market trading after the company priced its $5 million public offerin...
U.S. stocks traded mostly higher toward the end of trading, with the Nasdaq Composite gaining over 100 points on Monday. The Dow traded up 0.01% to...
Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline...
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 50 points on Monday. The Dow traded up 0.14% to 37,356.29...
U.S. stocks traded higher this morning, with the Dow Jones index gaining around 50 points on Monday. Following the market opening Monday, the Dow t...
News, Short Squeeze, Breakout and More Instantly...
inFoods ® IBS patients can now conveniently self-collect a blood sample using a simple finger-stick methodology in the privacy of their home inFoods ® IBS test is the first of its kind to identify specific foods that can trigger an Irritable Bowel Syndrome (I...
Biomerica (NASDAQ: BMRA) , a biomedical technology company that develops, patents, manufactures and markets advanced diagnostics and therapeutic products, has entered into an at-market issuance sales agreement with EF Hutton LLC and R.F. Lafferty & Co. Inc. According to the company, the agree...
With IBS affecting 10 to 15% of the global population, the associated $21 billion in direct medical costs and absenteeism underscores the urgent need of innovative solutions. Recognized as the 7th most common diagnosis by all physicians, IBS represents a significant healthcare burden. inF...